Research programme: neurokinin-1 receptor antagonists - OPKO Health

Drug Profile

Research programme: neurokinin-1 receptor antagonists - OPKO Health

Alternative Names: NK-1 antagonists - Schering-Plough; OPK 88002

Latest Information Update: 11 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer OPKO Health
  • Class Antiemetics; Antipruritics
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pruritus
  • No development reported Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 08 Aug 2017 OPKO Health's receives approval for an IND application for initiation of a phase IIa trial of OPK 88002 for Pruritus before August 2017
  • 08 Aug 2017 OPKO Health plans a phase IIa trial of OPK 88002 for Pruritus in late 2017
  • 09 May 2017 OPKO Health plans a phase IIa trial for Pruritus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top